Table 1.

Patients and tumor characteristics for EBC and MBC cohorts, including populations restricted to include only relapsed patients or those with clinical follow-up greater than 5 or 6 years

Characteristic	EBC all	EBC – relapsed or follow-up ≥5 years	EBC – relapsed or follow-up ≥6 years	MBC
Number	590	443	319	109
Age, mean (range)	42 (29–50)	42 (29–50)	42 (29–50)	39 (22–53)
Tumor size, n (%)
<2 cm	35 (5.9)	23 (5.2)	11 (3.5%)	—
2–5 cm	396 (67.1)	285 (64.3)	203 (63.6%)
>5 cm	159 (27)	135 (30.5)	105 (32.9%)
Grade, n (%)
I	74 (13)	63 (14)	46 (14)	—
II	300 (51)	224 (51)	162 (51)
III	115 (19)	89 (20)	73 (23)
Unknown	101 (17)	67 (15)	38 (12)
Lymph node status, n (%)
0	248 (42)	166 (37.5)	106 (33)	—
1–3	157 (27)	121 (27.5)	83 (26)
>3	185 (31)	156 (35)	130 (41)
HER2, n (%)
Positive	108 (18)	90 (20.5)	76 (24)	—
Negative	388 (66)	298 (67)	210 (66)
Unknown	94 (16)	55 (12.5)	33 (10)
ER, n (%)
Positive	552 (93.6)	410 (92.6)	297 (93)	—
Negative	37 (6.3)	32 (7.2)	22 (7)
Unknown	1 (0.2)	1 (0.2)	0 (0)
PR, n (%)
Positive	545 (92.4)	405 (91.4)	291 (91)	—
Negative	44 (7.4)	37 (8.4)	28 (9)
Unknown	1 (0.2)	1 (0.2)	0 (0)
Treatment arm, n (%)
A	186 (31.5)	142 (32.0)	106 (33.2)	—
B	216 (36.6)	158 (35.7)	111 (34.8)
C	188 (31.9)	143 (32.3)	102 (32.0)
Dominant metastatic site, n (%)
Soft tissue	—	—	—	79 (72.5)
Bone				17 (15.6)
Viscera				13 (11.9)
Prior systemic treatment, n (%)
No	—	—	—	69 (63.3)
Yes				40 (36.7)

NOTE: Treatment arm A: not in luteal phase at the time of trial entry, randomized to luteal phase surgery; treatment arm B: not in luteal phase at the time of trial entry, randomized to immediate, non-luteal phase surgery; and treatment arm C: in luteal phase at the time of trial entry, immediate surgery in luteal phase.

Abbreviation: PR, progesterone receptor.